Agenus (AGEN) Set to Post Quarterly Earnings on Thursday

Agenus (NASDAQ:AGEN) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Agenus to announce earnings of $0.02 per share and revenue of $28.20 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:30 AM ET.

Agenus (NASDAQ:AGEN) last posted its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. The firm had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million. On average, analysts expect Agenus to post ($0.30) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Agenus Price Performance

Shares of Agenus stock traded up $0.19 on Tuesday, reaching $6.72. 163,809 shares of the company were exchanged, compared to its average volume of 1,828,240. Agenus has a 1-year low of $2.71 and a 1-year high of $10.31. The stock’s 50 day moving average price is $7.56 and its 200-day moving average price is $4.95. The company has a market cap of $303.31 million, a P/E ratio of 2.61 and a beta of 1.54.

Analyst Ratings Changes

AGEN has been the subject of a number of research analyst reports. Rodman & Renshaw started coverage on Agenus in a research report on Monday, September 28th. They issued a “buy” rating and a $19.00 target price for the company. Weiss Ratings upgraded Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 8th. B. Riley Financial reissued a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Chardan Capital restated a “buy” rating on shares of Agenus in a research report on Thursday, October 22nd. Finally, Wall Street Zen cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $24.50.

About Agenus

Agenus Inc is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with a focus on therapies that may be used across multiple cancer types.

Agenus develops a range of therapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, bispecific antibodies and other antibody-based treatments. Its pipeline has included investigational therapies targeting immune-regulating pathways, as well as combination regimens intended to improve treatment responses and address resistance to existing cancer therapies.

The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011.